Want to see MNPR full AI Analyst Report?
MNPR Stock Chart & Stats
$110.82
$4.17(3.95%)
At close: 4:00 PM EDT
$110.82
$4.17(3.95%)
Day’s Range― - ―
52-Week Range$50.07 - $124.82
Previous CloseN/A
Volume229.82K
Average Volume (3M)148.10K
Market Cap
$523.35M
Enterprise Value$656.75M
Total Cash (Recent Filing)$134.30M
Total Debt (Recent Filing)$107.83K
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 06, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.34
Shares Outstanding6,712,172
10 Day Avg. Volume156,863
30 Day Avg. Volume148,103
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)3.51
Price to Sales (P/S)0.00
P/FCF Ratio-39.66
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-35.50
Forecast
1Y Price Target
$129.29Price Target Upside16.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.9
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Capital BaseNear-zero leverage reduces creditor pressure and preserves financial flexibility while the sizable equity and asset base supports continued development activity. This gives Monopar more capacity to pursue regulatory and clinical milestones than a similarly loss-making company carrying substantial debt.
ALXN1840 Regulatory ProgressBeginning the rolling NDA process is a material step toward potential U.S. commercialization of ALXN1840. It demonstrates that the lead program has advanced beyond clinical development into formal regulatory review, creating a clearer pathway to a future product-based revenue stream.
Late-stage Clinical ValidationPositive pivotal-trial results and durable clinical benefit strengthen the scientific and commercial foundation of Monopar’s lead asset. Combined with Fast Track, Orphan Drug, and Rare Pediatric Disease designations, this may support differentiation in the rare Wilson disease market if approval follows.
Bears Say
No Commercial RevenueZero reported revenue indicates that Monopar has not yet established a recurring product-based commercial model. Until a candidate is approved and launched, operations remain dependent on development progress and external funding rather than customer demand, making execution and regulatory outcomes critical.
Widening Net LossesThe widening loss trajectory shows that spending has increased without corresponding revenue or commercialization progress in the reported financials. Persistent losses can reduce the capital base over time and require additional financing, while also increasing the importance of successful clinical and regulatory execution.
Persistent Cash BurnSustained negative operating and free cash flow means the company is not internally funding its research and regulatory programs. Continued cash burn increases dependence on equity or other financing, which can constrain strategy and create funding pressure before any approved product generates revenue.
Monopar Therapeutics Inc News
MNPR FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $50.07 and its highest was $124.82 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Monopar Therapeutics Inc’s market cap is $523.35M.
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s upcoming earnings report date is Nov 06, 2026 which is in 31 days.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.647 by $0.027.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate is -0.8.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 6,712,172 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.647. Following the earnings report the stock price went up 0.384%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Currently, no hedge funds are holding shares in MNPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monopar Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$129.29 (16.66% Upside)
$129.29 (16.66% Upside)
Blogger Sentiment
Bullish
MNPR Sentiment 75%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 53.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 12.8%
Last 30 Days ▼ 12.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
150.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
MNPR Stock 12 Month Forecast
Average Price Target
$129.29
▲(16.66% Upside)
Technical Analysis
CytomX Therapeutics
―
Kura Oncology
―
Replimune Group
―
Oric Pharmaceuticals
―
Candel Therapeutics
―
Ownership Overview
14.02% Insiders
6.75% Mutual Funds
48.31% Other Institutional Investors
21.84% Public Companies and
Individual Investors